A detailed history of Bank Of America Corp transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 2,081,888 shares of TGTX stock, worth $46.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,081,888
Previous 2,201,450 5.43%
Holding current value
$46.3 Million
Previous $33.5 Million 10.61%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$13.32 - $19.19 $1.59 Million - $2.29 Million
-119,562 Reduced 5.43%
2,081,888 $37 Million
Q1 2024

May 15, 2024

BUY
$13.02 - $21.3 $21.1 Million - $34.5 Million
1,618,362 Added 277.55%
2,201,450 $33.5 Million
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $1.8 Million - $5.06 Million
268,812 Added 85.53%
583,088 $9.96 Million
Q2 2023

Aug 14, 2023

SELL
$15.48 - $35.0 $6.44 Million - $14.6 Million
-416,250 Reduced 56.98%
314,276 $7.81 Million
Q1 2023

May 12, 2023

SELL
$10.23 - $19.34 $1.7 Million - $3.22 Million
-166,524 Reduced 18.56%
730,526 $11 Million
Q4 2022

Feb 10, 2023

SELL
$5.01 - $11.83 $383,675 - $905,965
-76,582 Reduced 7.87%
897,050 $10.6 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $740,504 - $1.36 Million
162,036 Added 19.97%
973,632 $5.76 Million
Q2 2022

Aug 12, 2022

SELL
$3.74 - $10.66 $332,601 - $948,004
-88,931 Reduced 9.88%
811,596 $3.45 Million
Q1 2022

May 16, 2022

BUY
$7.81 - $20.45 $2.07 Million - $5.42 Million
264,866 Added 41.67%
900,527 $8.57 Million
Q4 2021

Feb 08, 2022

BUY
$15.2 - $35.51 $2.95 Million - $6.89 Million
194,084 Added 43.95%
635,661 $12.1 Million
Q3 2021

Nov 15, 2021

SELL
$21.78 - $40.45 $929,657 - $1.73 Million
-42,684 Reduced 8.81%
441,577 $14.7 Million
Q2 2021

Sep 13, 2021

BUY
$32.5 - $48.96 $15.7 Million - $23.7 Million
484,261 New
484,261 $18.8 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $3.23B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.